TABLE 1.
LC-MS/MS analysis of AR modifications regulated by CDK5.
| CDK5 in vitro phosphorylationb,c | In vivo | ||||
|---|---|---|---|---|---|
| Amino acids | Peptide sequencea | Modification | CDK5/p25 | CDK5/p25 + roscovitine | CDK5 siRNAb,d |
| 10–17 | VYPrPPSK | R13 (methyl) | — | — | — |
| VYPrPPSK | R13 (dimethyl) | — | — | — | |
| 84–99 | QQQQQQGEDGsPQAHR | S94 (phospho) | — | — | — |
| 300–311 | STEDTAEYsPFK | S308 (phospho) | Induced | Suppressede | Suppressed |
| 511–520 | VPYPsPTcVK | S515 (phospho) | — | — | — |
| 639–658 | LQEEGEASSTTsPTEETTQK | S650 (phospho) | — | — | — |
aLowercase letters represent modified amino acid residues. c, carbamidomethylated cysteine.
bFor phosphopeptides, quantitative results consistent before and after TiO2 phosphopeptide enrichment were taken into consideration.
cAR immunoprecipitated from VCaP cells used.
dLNCaP cells used.
eCompared to CDK5-induced phosphopeptides.